The stock's rise snapped a three-day losing streak.

Novavax on Thursday tried to calm investors spooked by the delay of full approval of its COVID vaccine shot by U.S.

Novavax Inc. (NASDAQ:NVAX) reported first-quarter 2025 sales of $667 million, compared to $94 million a year ago, beating the ...

Novavax (NASDAQ:NVAX) pivots back to profitability after delivering a $666.7 million revenue haul in Q1surpassing estimates ...

Novavax is set to release its quarterly earnings on May 9, 2025, with analysts expecting earnings per share of $0.19 and projected revenue of $204.1 million. The company’s recent multi-billion-dollar ...

QBTS: D-Wave Quantum shares are rallying after the company beat analysts' estimates and reported record quarterly revenue ...

Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ETCompany ParticipantsLuis Sanay - Vice President, Investor ...

After more than a month of speculation over how the FDA will rule on Novavax’s application for an updated formulation of its ...

Shares of Novavax, Inc. (NVAX) traded 16% higher on Thursday morning after the company reported upbeat first-quarter (Q1) ...

Novavax (NVAX) stock jumps 35% as the company raises its 2025 revenue outlook and its Q1 2025 financials surpasses forecasts ...

Shares of the company surged 23% in premarket trading after the company swung to profit in the first quarter, helped by reduced costs tied to the development and sale of its COVID-19 vaccine, its only ...

Shares of the company rose 8.74% to $6.47 in premarket trading. Novavax, whose protein-based shot uses an older technology, missed out on the pandemic vaccine windfall – enjoyed by rivals Moderna and ...